FDA delays Thrombin review

08/23/2007 | SeattlePI.com

The FDA has postponed completing a review of ZymoGenetics' blood-clotting drug Thrombin so it can further examine manufacturing data, the company announced. The review now is expected to be completed by Jan. 17 of next year.

View Full Article in:

SeattlePI.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD